The green tea catechins, (−)-Epigallocatechin-3-gallate (EGCG) and (−)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells

Catechins Inhibit CCL20 Production in IL-17A-Stimulated Human Gingival Fibroblasts

“…Moreover, Chae et al reported that EGCG suppressed ERK phosphorylation in angiotensin 2-treated human umbilical vein endothelial cells [23]. Bigelow et al also reported that EGCG and ECG suppressed ERK activation in hepatocyte growth factor-treated tumorigenic breast epithelial cells [24]. Their reports support the results found in this study.…”

Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis

“…EGCG, a natural phytochemical has been shown to have multimodal mechanisms of action. We and others have shown that at cellular level it inhibits AKT expression and activation while interfering with the bcl2 expression presumably by decreasing its stability Bigelow and Cardelli, 2006;Qin et al, 2007). These observations strongly advocate employment of EGCG to overcome TRAIL resistance in various cancers including CaP especially those with constitutively active AR-AKT-bcl2 expression.…”

Adaptive Cellular Stress Pathways as Therapeutic Targets of Dietary Phytochemicals: Focus on the Nervous System

“…For example, EGCG inhibits cell proliferation and epidermal growth factor-dependent activation of ERK1/ERK2 in immortalized cervical cells (ECE16-1) (Sah et al, 2004). The green tea catechins (EGCG and epicatechin gallate) inhibit hepatocyte growth factorinduced Met phosphorylation and downstream activation of Akt and ERK to suppress invasive cancer growth in breast carcinoma and prostate cancer cells (Bigelow and Cardelli, 2006;Duhon et al, 2010). Green tea polyphenols and caffeine inhibited cell proliferation, enhanced apoptosis, and lowered levels of c-Jun and phosphorylated ERK1/ERK2 in a lung tumor progression model of mice .…”